Catalent Invests $350m In Bloomington As Recipharm Ties Up Deals
Multi-Year Investment Delivers On Catalent Promise To Continue Expansion
In the burgeoning biologics CDMO space, Catalent has announced further investment at its flagship campus in Bloomington, Indiana, while Recipharm has wrapped up a pair of deals that will beef up the Sweden-based firm’s presence in the US.
